Semaglutide 10mg

Compound Name: Semaglutide
Synonyms: NN9535
CAS Number: 910463-68-2
Molecular Formula: C187H291N45O59
Molecular Weight: ~4113.58 g/mol
Structure: Peptide sequence with modifications to enhance stability; includes Aib at position 8, Arg at position 34, and a C18 fatty diacid moiety attached to lysine 26 via a hydrophilic spacer.
Peptide Sequence: H-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gln-Lys-Ala-Ala-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-NH₂

Chemical Structure:

Source: PubChem

Mechanism of Action: Semaglutide is a potent, selective GLP-1 receptor agonist. It stimulates the GLP-1 receptor in pancreatic β-cells to enhance glucose-dependent insulin secretion, suppresses pancreatic α-cell glucagon secretion, and directly acts on appetite-regulating centers in the brain. The result is pronounced postprandial and fasting blood glucose reduction, delayed gastric emptying (transient), reduced hunger, enhanced satiety, and decreased caloric intake. Structural modifications protect against DPP-4 degradation and extend the peptide’s half-life, allowing once-weekly dosing

Biological Activity:

• Potent GLP-1 receptor agonist
• Enhances insulin secretion (glucose-dependent)
• Suppresses glucagon secretion
• Reduces appetite and caloric intake
• Produces significant, sustained body weight loss
• Improves cardiometabolic risk factors (glycemia, blood pressure, lipids)

Storage: Refrigerate once reconstituted. Protect from light and moisture.

Drug Categories: Amino Acids, Peptides, and Proteins; Lipids

Additional Notes:

• Engineered for DPP-IV resistance and long half-life via fatty-acid conjugation
• Demonstrates the highest anti-obesity efficacy of any currently approved agent

Summary Table:

Disclaimer: For Research Use Only. Not intended for human or veterinary use. This compound is supplied solely for laboratory and R&D purposes.

Detailed Product Description

Semaglutide is a modified GLP-1 analog containing 94% sequence homology with native human GLP-1. Key structural changes—Aib substitution at position 8, Arg at position 34, and C18 fatty diacid conjugation at Lys26—enable reversible albumin binding and confer resistance to DPP-4-mediated degradation. This results in a long half-life (approximately 7 days), making it suitable for once-weekly subcutaneous injection. Semaglutide robustly reduces appetite, promotes satiety, and significantly decreases body weight and glycemic parameters in both obese/overweight individuals and those with type 2 diabetes.

Research Highlights

• Sustained Weight Loss: Reductions of 8–16%+ of baseline body weight over 1–2 years; 86% of patients lose at least 5% of baseline weight; up to 32% lose ≥20%
• Glycemic Control: HbA1c reductions up to 1.9% vs placebo, with effects on both fasting and postprandial glucose
• Cardiometabolic Improvement: Decreases in blood pressure, waist circumference, lipid fractions, and inflammatory biomarkers; improved quality of life metrics
• Head-to-Head Studies: Outperforms once-daily liraglutide 3.0 mg, orlistat, phentermine–topiramate, and naltrexone–bupropion for weight loss efficacy

Mechanism of Action

Semaglutide exerts its pharmacological activity by high-affinity, selective activation of the GLP-1 receptor on pancreatic β-cells, α-cells, and key appetite-regulating neuronal circuits:

• Pancreas: Enhanced glucose-dependent insulin secretion; glucagon suppression, lowering hepatic glucose output
• Central Nervous System: Decreases food intake by targeting homeostatic and hedonic appetite pathways (hindbrain/hypothalamus), reducing hunger and cravings, and enhancing satiety
• Gastrointestinal Tract: Delays gastric emptying, contributing to satiety (transient effect at higher doses)
• Adiposity/Energy Intake: Weight loss is primarily driven by sustained reduction in caloric intake, not increased energy expenditure

Pharmacokinetic Profile:

• Route of Administration: Subcutaneous
• Dosing Frequency: Once weekly (subcutaneous)
• Half-Life: ~155–184 hours (6.5–7.7 days), supporting once-weekly SC dosing
• Formulation:

Formulation & Handling

• Reconstitute in sterile water or PBS (pH ~7.4) for in vivo/in vitro use
• Store at –20°C in aliquots to prevent freeze-thaw degradation
• Shelf-stable for 12 months under recommended storage condition

Clinical Trial Activity (Selected)

References

Wilding, J. P. H. et al. Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med. 384, 989–1002 (2021). https://doi.org/10.1056/NEJMoa2032183

Davies, M. et al. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial. JAMA 318, 1460–1470 (2017). https://doi.org/10.1001/jama.2017.14752

Lau, D. C. W., Batterham, R. L. & le Roux, C. W. Pharmacological profile of once-weekly injectable semaglutide for chronic weight management. Expert Rev. Clin. Pharmacol. 15, 251–268 (2022). https://doi.org/10.1080/17512433.2022.2070473

Rubino, D. et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA 325, 1414–1425 (2021). https://doi.org/10.1001/jama.2021.3224

Lambers Heerspink, H. J. et al. Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial. Nat. Med. 31, 278–285 (2025). https://doi.org/10.1038/s41591-024-03327-6